Drug shortage
Riluzole Oral Suspension · EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)
FDA drug shortage · Current · updated Apr 15, 2025
Key facts
| Generic name | Riluzole Oral Suspension |
|---|---|
| Proprietary name | Tiglutik |
| Company | EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) |
| Presentation | Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-2) |
| Dosage form | Oral Suspension |
| Strength | 50 mg/10 mL |
| Status | Current |
| Reason for shortage | Requirements related to complying with good manufacturing practices |
| Therapeutic category | Neurology |
| Package NDCs | 70726-0303-2 |
| First posted | Jan 26, 2024 |
| Last updated | Apr 15, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: